ticagrelor or prasugrel .
ApprovedSmall molecule
ticagrelor or prasugrel . is one of 46 small molecule programs targeting Aneurysm. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
71 competitors in Aneurysm
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Tecfidera
BiogenApproved
Pletal
OtsukaApproved
Xarelto
WWim Janssens
Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Bayer Aspirin
BayerPhase 3
Coumadin
AAbbott
Approved
Brilinta
AstraZenecaPhase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Approved
Zocor
OOrganon and Co
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Aneurysm1 trial
Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia
Recruiting·FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·Phase 4·NCT06400940·640 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ticagrelor or prasugrel .. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details